Changeflow GovPing Healthcare & Life Sciences Virus-like Particles Patent Granted to Universi...
Routine Notice Added Final

Virus-like Particles Patent Granted to University of Denver

Favicon for changeflow.com USPTO Patent Grants - Peptides (C07K)
Published
Detected
Email

Summary

The USPTO granted Patent US12594329B2 to the University of Denver on April 7, 2026. The patent covers virus-like particles, compositions, antibody detection tests using virus-like particles, and methods of producing non-replicating virus-like particles from modified viral genomes. Schuyler B. van Engelenburg is the sole inventor of the 9-claim patent.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

The USPTO issued Patent US12594329B2 (Kind B2) to the University of Denver for virus-like particle technology. The patent discloses methods for generating modified viral genomes with portions removed to produce non-replicating virus-like particles, along with related compositions and antibody detection tests. The patent was filed November 9, 2021, under application number 17522150, and contains 9 claims.

This patent grant establishes exclusionary intellectual property rights for the University of Denver in the virus-like particle technology space. Organizations engaged in virus-like particle research or development should evaluate whether their activities may fall within the scope of these claims to assess potential licensing needs or freedom-to-operate concerns.

Archived snapshot

Apr 7, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Virus-like particles

Grant US12594329B2 Kind: B2 Apr 07, 2026

Assignee

University of Denver

Inventors

Schuyler B. van Engelenburg

Abstract

Virus-like particles, compositions and antibody detection tests with virus-like particles, and a method of producing virus-like particles are disclosed. The method includes generating a modified viral genome based on a viral genome, wherein a portion of the viral genome is removed to generate the modified viral genome configured to yield virus-like particles that are unable to replicate, and producing one or more virus-like particles using the modified viral genome.

CPC Classifications

C07K 14/005 C07K 14/165 C07K 2319/00 C07K 14/08 C12N 2770/20023

Filing Date

2021-11-09

Application No.

17522150

Claims

9

View original document →

Get daily alerts for USPTO Patent Grants - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 7th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US12594329B2

Who this affects

Applies to
Educational institutions Healthcare providers Biotechnology companies
Industry sector
3254.1 Biotechnology
Activity scope
Patent Rights
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Healthcare Pharmaceuticals

Get alerts for this source

We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!